Pharmacological agents for adults with acute respiratory distress syndrome

Cochrane Database of Systematic Reviews

Volumn 2019, Issue 7, 2019, Pages

  Lewis, Sharon R ^a   Pritchard, Michael W ^a   Thomas, Carmel M ^b   Smith, Andrew F ^a  

^a ROYAL LANCASTER INFIRMARY   (United Kingdom)

^b GREATER MANCHESTER MENTAL HEALTH NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ANISODIMINE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLYCERYL TRINITRATE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LEVOSIMENDAN; LISOFYLLINE; LUNG SURFACTANT; OXOTHIAZOLIDINE 4 CARBOXYLIC ACID; PALIFERMIN; PENEHYCLIDINE HYDROCHLORIDE; PROSTACYCLIN; RESPIRATORY TRACT AGENT; SIVELESTAT; SOLNATIDE; ULINASTATIN; UNCLASSIFIED DRUG; NEUROMUSCULAR BLOCKING AGENT;

ACUTE LUNG INJURY; ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; ALL CAUSE MORTALITY; ARTICLE; ARTIFICIAL VENTILATION; CLINICAL EFFECTIVENESS; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; FITNESS; HUMAN; MESENCHYMAL STEM CELL; MORTALITY RATE; PRIORITY JOURNAL; SYSTEMATIC REVIEW; TREATMENT OUTCOME; MORTALITY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADRENAL CORTEX HORMONES; ADULT; HUMANS; NEUROMUSCULAR BLOCKING AGENTS; PULMONARY SURFACTANTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESPIRATION, ARTIFICIAL; RESPIRATORY DISTRESS SYNDROME, ADULT;

EID: 85069831167     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD004477.pub3     Document Type: Article

References (193)

1. 2-agonist for treatment of acute lung injury. American Journal of Respiratory and Critical Care Medicine 2011;184(5):561–8. PUBMED: 21562125]
2. 2-agonist for treatment of acute lung injury. American Journal of Respiratory and Critical Care Medicine 2013;188(11):1378.
3. The ARDS Clinical Trials Network, National Heart, Lung and Blood Institute, National Institutes of Health. Randomized, placebo-controlled trial of lisofylline for early treatment of acute lung injury and acute respiratory distress syndrome. Critical Care Medicine 2002;30(1):1–6. PUBMED: 11902249]
4. Gao F, Thickett DR. In vivo and in vitro effects of salbutamol on alveolar epithelial repair in acute lung injury. Thorax 2008;63(3):215–20. PUBMED: 17951278]
5. ∗ Perkins GD, McAuley DF, Thickett DR, Gao F. The ß-agonist lung injury trial (BALTI). American Journal of Respiratory and Critical Care Medicine 2006;173(3):281–7. PUBMED: 16254268]
6. Gao Smith F, Perkins GD, Gates S, Young D, McAuley DF, Tunnicliffe W, et al. Effect of intravenous beta-2 agonist treatment on clinical outcomes in acute respiratory distress syndrome (BALTI-2): a multicentre, randomised controlled trial. Lancet 2012;379(9812):229–35. PUBMED: 22166903]
7. ∗ Gates S, Perkins GD, Lamb SE, Kelly C, Thickett DR, Young JD, et al. Beta-agonist lung injury trIal-2 (BALTI-2): a multicentre, randomised, double-blind, placebo-controlled trial and economic evaluation of intravenous infusion of salbutamol versus placebo in patients with acute respiratory distress syndrome. Health Technology Assessment 2013;17(38):v-vi: 1-87. PUBMED: 24028755]
8. Perkins GD, Gates S, Lamb SE, McCabe C, Young D, Gao F. Beta agonist lung injury trIal-2 (BALTI-2) trial protocol: a randomised, double-blind, placebo-controlled of intravenous infusion of salbutamol in the acute respiratory distress syndrome. Trials 2011;12:113.
9. Barrese-Perez Y, Hidalgo-Sanchez AO, Avila-Albuerne Y, Uranga-Pina R, Diaz-Casanas E, Fernandez-Limia O. Pulmonary surfactant exogenous in adults with acute respiratory distress syndrome. Revista del Instituto Nacional de Enfermedades Respiratorias 2015;74(3):176–8.
10. Chen Y, Luo JJ, Jiang DX, Lin YP, Tong HS, Su L. Effect of ulinastatin on acute lung injury induced by severe heat stroke and its mechanism. Medical Journal of Chinese People’s Liberation Army 2017;42(4):301–6. Embase: 616874253]
11. Endo S, Sato N, Yaegashi Y, Suzuki Y, Kojika M, Yamada Y, et al. Sivelestat sodium hydrate improves septic acute lung injury by reducing alveolar dysfunction. Research Communications in Molecular Pathology and Pharmacology 2006;119(1-6):53–65. PUBMED: 17974096]
12. Guoshou Z, Chengye Z, Zhihui L, Jinlong L. Effects of high dose of anisodamine on the respiratory function of patients with traumatic acute lung injury. Cell Biochemistry and Biophysics 2013;66(2):365–9. PUBMED: 23504631]
13. Brealey D, Hargreaves I, Land J, Singer M, McAuley D. Plasma ubiquinone levels are unaffected by simvastatin in acute lung injury. Intensive Care Medicine 2012;38:S64.
14. ∗ Craig TR, Duffy MJ, Shyamsundar M, McDowell C, O’Kane CM, Elborn JS, et al. A randomized clinical trial of hydroxymethylglutaryl-coenzyme a reductase inhibition for acute lung injury (the HARP study). American Journal of Respiratory and Critical Care Medicine 2011;183(5):620–6. PUBMED: 20870757]
15. Craig TR, Duffy MJ, Shyamsundar M, McDowell C, O’Kane CM, Elborn JS, et al. Erratum: a randomized clinical trial of hydroxymethylglutaryl-coenzyme a reductase inhibition for acute lung injury (the HARP study). American Journal of Respiratory and Critical Care Medicine 2014;190(10):1199–200.
16. Craig TR, Duffy MJ, Shyamsundar M, O’Kane C, Elborn JS, McAuley DF. Simvastatin reduces inflammation and improves clinical outcomes in ALI: results of The HARP Study. Thorax 2009;64:A2.
17. Craig TR, Duffy MJ, Shyamsundar M, O’Kane CM, Elborn JS, McAuley DF. Results of the HARP study: a randomized double blind phase II trial of 80mg simvastatin in acute lung injury. American Journal of Respiratory and Critical Care Medicine. Conference: American Thoracic Society International Conference, ATS. 2010; Vol. 181: no pagination.
18. McAuley DF, O’Kane CM, Craig TR, Shyamsundar M, Herwald H, Dib K. Simvastatin decreases the level of heparin-binding protein in patients with acute lung injury. BMC Pulmonary Medicine 2013;13:47.
19. Laffey JG, O’Kane CM, Cross M, Perkins GD, Murphy L, McNally C, et al. Hydroxymethylglutaryl-CoA reductase inhibition with simvastatin in acute lung injury to reduce pulmonary dysfunction (HARP-2) trial: study protocol for a randomized controlled trial. Trials 2012;13(170):1–9. PUBMED: 22985805]
20. ∗ McAuley DF, Laffey JG, O’Kane CM, Perkins GD, Mullan B, Trinder T, et al. Simvastatin in the acute respiratory distress syndrome. New England Journal of Medicine 2014;371(18):1695–703. PUBMED: 25268516]
21. McAuley DF, Laffey JG, O’Kane CM, Perkins GD, Mullan B, Trinder TJ, et al. SImvastatin to reduce pulmonary dysfunction in patients with acute respiratory distress syndrome: the HARP-2 RCT. Efficacy and Mechanism Evaluation 2018;5(1): no pagination. PUBMED: 29400921]
22. Huang SR, Ma AY, Liu Y, Qu Y. Effects of inflammatory factors including plasma tumor necrosis factor-alpha in the clinical treatment of acute respiratory distress syndrome. Oncology Letters 2017;13(6):5016–20. PUBMED: 28599503]
23. Ji M, Chen T, Wang B, Chen M, Ding Q, Chen L, et al. Effects of ulinastatin combined with mechanical ventilation on oxygen metabolism, inflammation and stress response and antioxidant capacity of ARDS. Experimental and Therapeutic Medicine 2018;15(6):4665–70. PUBMED: 29805484]
24. Kadoi Y, Hinohara H, Kunimoto F, Saito S, Goto F, Kosaka T, et al. Pilot study of the effects of ONO-5046 in patients with acute respiratory distress syndrome. Anesthesia and Analgesia 2004;99(3):872–7. PUBMED: 15333424]
25. Cross LJ, O’Kane CM, McDowell C, Elborn JJ, Matthay MA, McAuley DF. Erratum: keratinocyte growth factor in acute lung injury to reduce pulmonary dysfunction-a randomised placebo-controlled trial (KARE): study protocol. Trials 2017;18(1):214. PUBMED: 28494790]
26. Cross LJ, O’Kane CM, McDowell C, Elborn JJ, Matthay MA, McAuley DF. Keratinocyte growth factor in acute lung injury to reduce pulmonary dysfunction-a randomised placebo-controlled trial (KARE): study protocol. Trials 2013;14:51. PUBMED: 23419093]
27. ∗ McAuley DF, Cross LJ, Hamid U, Gardner E, Elborn JS, Cullen KM, et al. Keratinocyte growth factor for the treatment of the acute respiratory distress syndrome (KARE): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Respiratory Medicine 2017;5(6): 484–91. PUBMED: 28526233]
28. National Heart Lung and Blood Institute, The ARDS Clinical Trials Network. Ketoconazole for early treatment of acute lung injury and acute respiratory distress syndrome: a randomized controlled trial. JAMA 2000;283(15): 1995–2002. PUBMED: 10789668]
29. Kesecioglu J, Schultz MJ, Lundberg D, Lauven PM, Lachmann B. Treatment of acute lung injury (ALI/ARDS) with surfactant. American Journal of Respiratory and Critical Care Medicine 2001;163(5 Pt. 2):A819.
30. Kesecioglu J, Beale R, Stewart TE, Findlay GP, Rouby JJ, Holzapfel L, et al. Exogenous natural surfactant for treatment of acute lung injury and the acute respiratory distress syndrome. American Journal of Respiratory and Critical Care Medicine 2009;180(10):989–94. PUBMED: 19713451]
31. Khan A, Benthin C, Zeno B, Albertson T, Boyd J, Christie J, et al. A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome. Critical Care 2017;21(1):234. PUBMED: 28877748]
32. Krenn K, Lucas R, Croizé A, Boehme S, Klein KU, Hermann R, et al. Inhaled AP301 for treatment of pulmonary edema in mechanically ventilated patients with acute respiratory distress syndrome: a phase IIa randomized placebo-controlled trial. Critical Care 2017;21(1):194. PUBMED: 28750677]
33. Li BQ, Sun HC, Nie SN, Shao DB, Liu HM, Qian XM. Effect of penehyclidine hydrochloride on patients with acute lung injury and its mechanisms. Chinese Journal of Traumatology-English Edition 2010;13(6):329–35. PUBMED: 21126389]
34. Liu L, Li J, Huang YZ, Liu SQ, Yang CS, Guo FM, et al. The effect of stress dose glucocorticoid on patients with acute respiratory distress syndrome combined with critical illness-related corticosteroid insufficiency. Chinese Journal of Internal Medicine 2012;51(8):599–603. PUBMED: 23158856]
35. Liu LP, Li B, Zhu L, Dou ZM, Li YM. Clinical efficacy of nitroglycerin in patients with septic shock with ARDS. Medical Journal of Chinese People’s Liberation Army 2015;40 (8):647–51. EMBASE: 2015326178]
36. Liu LP, Hu SW, Shuai TK, Deng YY, Wang LJ, Li YM. Clinical effect of alprostadil in patients with septic shock associated with acute respiratory distress syndrome. Medical Journal of Chinese People’s Liberation Army 2017;42(9): 805–9. Embase: 20170777094]
37. Meduri GU, Golden E, Freire AX, Taylor E, Zaman M, Carson SJ, et al. Methylprednisolone infusion in early severe ARDS results of a randomized controlled trial. Chest 2009;136(5 Suppl):e30. Embase: 358384513]
38. ∗ Meduri GU, Golden E, Freire AX, Taylor E, Zaman M, Carson SJ, et al. Methylprednisolone infusion in early severe ARDS: results of a randomized controlled trial. Chest 2007;131(4):954–63. PUBMED: 17426195]
39. Mohamed HS, Meguid MM. Effect of nebulized budesonide on respiratory mechanics and oxygenation in acute lung injury/acute respiratory distress syndrome: randomized controlled study. Saudi Journal of Anaesthesia 2017;11(1): 9–14. PUBMED: 28217046]
40. Morelli A, Teboul JL, Maggiore SM, Vieillard-Baron A, Rocco M, Conti G, et al. Effects of levosimendan on right ventricular afterload in patients with acute respiratory distress syndrome: a pilot study. Critical Care Medicine 2006;34(9):2287–93. PUBMED: 16791109]
41. Morris PE, Papadakos P, Russell JA, Wunderink R, Schuster DP, Truwit JD, et al. A double-blind placebo-controlled study to evaluate the safety and efficacy of L-2-oxothiazolidine-4-carboxylic acid in the treatment of patients with acute respiratory distress syndrome. Critical Care Medicine 2008;36(3):782–8. PUBMED: 18209670]
42. Najafi A, Mojtahedzadeh M, Mahmoodpoor A, Aghamohammadi M, Ahmadi A, Nahreini S, et al. Effect of N-acetylcysteine on microalbuminuria in patients with acute respiratory distress syndrome. Archives of Medical Science 2009;5(3):408–4. EMBASE: 358052253]
43. Ortolani O, Conti A, De Gaudio AR, Masoni M, Novelli G. Protective effects of N-acetylcysteine and rutin on the lipid peroxidation of the lung epithelium during the adult respiratory distress syndrome. Shock 2000;13(1):14–8. PUBMED: 10638663]
44. Coley C, Dechert R, Harding S, Paine R, Moss M, Martin GS, et al. Granulocyte macrophage colony stimulating factor is associated with decreased quality of life at 180 days post-event when administered to patients with acute lung injury. American Journal of Respiratory and Critical Care Medicine. Conference: American Thoracic Society International Conference, ATS 2012;185:no pagination. Embase: 71986815]
45. ∗ Paine R, Standiford TJ, Dechert RE, Moss M, Martin GS, Rosenberg AL, et al. A randomized trial of recombinant human granulocyte-macrophage colony stimulating factor for patients with acute lung injury. Critical Care Medicine 2012;40(1):90–7. PUBMED: 21926600]
46. Rezk NA, Ibrahim AM. Effects of methyl prednisolone in early ARDS. Egyptian Journal of Chest Diseases and Tuberculosis 2013;62(1):167–72. EMBASE: 369315254]
47. Ryugo M, Sawa Y, Takano H, Matsumiya G, Iwai S, Ono M, et al. Effect of a polymorphonuclear elastase inhibitor (sivelestat sodium) on acute lung injury after cardiopulmonary bypass: findings of a double-blind randomized study. Surgery Today 2006;36(4):321–6. PUBMED: 16554988]
48. Dinglas VD, Hopkins RO, Wozniak AW, Hough CL, Morris PE, Jackson JC, et al. One-year outcomes of rosuvastatin versus placebo in sepsis-associated acute respiratory distress syndrome: prospective follow-up of SAILS randomised trial. Thorax 2016;71(5):401–10. PUBMED: 26936876]
49. Hsu RK, Truwit JD, Matthay MA, Levitt JE, Thompson BT, Liu KD. Effect of rosuvastatin on acute kidney injury in sepsis-associated acute respiratory distress syndrome. Canadian Journal of Kidney Health and Disease 2018;5:1–8. PUBMED: 30116543]
50. Needham DM, Colantuoni E, Dinglas VD, Hough CL, Wozniak AW, Jackson JC, et al. Rosuvastatin versus placebo for delirium in intensive care and subsequent cognitive impairment in patients with sepsis-associated acute respiratory distress syndrome: an ancillary study to a randomised controlled trial. Lancet Respiratory Medicine 2016;4(3):203–12. PUBMED: 26832963]
51. Rogers A, Guan J, Hunninghake GM, Trtchounian A, Liu K, Matthay MA, et al. Inflammasome activation is associated with ARDS mortality, particularly in patients randomized to statin therapy. American Journal of Respiratory and Critical Care Medicine 2017;195:no pagination. Embase: 617705951]
52. Truwit JD, Bernard GR, Steingrub J, Matthay MA, Liu K, Albertson TE, et al. Sails: Statins for acutely injured lungs (ARDS) from sepsis. American Journal of Respiratory and Critical Care Medicine. Conference: American Thoracic Society International Conference, ATS 2014;189:no pagination. Embase: 72047035]
53. ∗ Truwit JD, Bernard GR, Steingrub J, Matthay MA, Liu KD, Albertson TE, et al. Rosuvastatin for sepsis-associated acute respiratory distress syndrome. New England Journal of Medicine 2014;370(23):2191–200. PUBMED: 24835849]
54. Soltan-Sharifi MS, Mojtahedzadeh M, Najafi A, Reza Khajavi M, Reza Rouini M, Moradi M, et al. Improvement by N-acetylcysteine of acute respiratory distress syndrome through increasing intracellular glutathione, and extracellular thiol molecules and anti-oxidant power: evidence for underlying toxicological mechanisms. Human and Experimental Toxicology 2007;26(9):697–703. PUBMED: 17984140]
55. Spragg RG, Lewis JF, Rathgeb F, Hafner D, Seeger W. Intratracheal instillation of rSP-C surfactant improves oxygenation in patients with ARDS. American Journal of Respiratory and Critical Care Medicine 2002;165(5 Pt. 2): A22.
56. Spragg RG, Lewis JF, Rathgeb F, Hafner D, Seeger W. Intratracheal instillation of rSP-C surfactant improves oxygenation in patients with ARDS. American Journal of Respiratory and Critical Care Medicine 2002;165(5 Pt. 2): A22.
57. Spragg RG, Lewis JF, Wurst W, Häfner D, Baughman RP, Wewers MD. Treatment of acute respiratory distress syndrome with recombinant surfactant protein C surfactant. American Journal of Respiratory and Critical Care Medicine 2003;185(1):1562–6. PUBMED: 12649125]
58. Liu KD, Wilson JG, Zhuo H, Caballero L, McMillan ML, Fang X, et al. Design and implementation of the START (stem cells for ARDS treatment) trial, a phase 1/2 trial of human mesenchymal stem/stromal cells for the treatment of moderate-severe acute respiratory distress syndrome. Annals of Intensive Care 2014;4(1):1–9. PUBMED: 25593740]
59. ∗ Matthay MA, Calfee CS, Zhuo H, Thompson BT, Wilson JG, Levitt JE, et al. Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial. Lancet Respiratory Medicine 2019; Vol. 7, issue 2: 154–62. PUBMED: 30455077]
60. Meduri GU, Bridges L, Siemieniuk RA, Kocak M. An exploratory reanalysis of the randomized trial on efficacy of corticosteroids as rescue therapy for the late phase of acute respiratory distress syndrome. Critical Care Medicine 2018; 46(6):884–91. PUBMED: 29432350]
61. ∗ Steinberg KP, Hudson LD, Goodman RB, Hough CL, Lanken PN, Hyzy R, et al. Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome. New England Journal of Medicine 2006;354(16): 1671–84. PUBMED: 16625008]
62. Zeiher BG, Artigas A, Vincent JL, Dmitrienko A, Jackson K, Thompson BT, et al. Neutrophil elastase inhibition in acute lung injury: results of the STRIVE study. Critical Care Medicine 2004;32(8):1695–702. PUBMED: 15286546]
63. ∗ Tongyoo S, Permpikul C, Mongkolpun W, Vattanavanit V, Udompanturak S, Kocak M, et al. Hydrocortisone treatment in early sepsis-associated acute respiratory distress syndrome: results of a randomized controlled trial. Critical Care 2016;20(1):329. PUBMED: 27741949]
64. Tongyoo S, Permpikul C, Vattanavanit V, Mongkolpun W. Hydrocortisone in treatment of severe sepsis and septic shock with acute respiratory distress syndrome: a randomised controlled trial. Intensive Care Medicine Experimental 2015;3:no pagination. Embase: 611853166]
65. Tsangaris I, Galiatsou E, Kostanti E, Nakos G. The effect of exogenous surfactant in patients with lung contusions and acute lung injury. Intensive Care Medicine 2007;33(5): 851–5. PUBMED: 17377767]
66. Vincent JL, Brase R, Santman F, Suter PM, McLuckie A, Dhainaut JF, et al. A multi-centre, double-blind, placebo-controlled study of liposomal prostaglandin E1 (TLC C-53) in patients with acute respiratory distress syndrome. Intensive Care Medicine 2001;27(10):1578–83. PUBMED: 11685297]
67. Walmrath D, De Vaal JB, Bruining HA, Kilian JG, Papazian L, Hohlfeld J, et al. Treatment of ARDS with a recombinant SP-C (rSP-C) based synthetic surfactant. American Journal of Respiratory and Critical Care Medicine 2000;161:A379.
68. Willson DF, Truwit JD, Conaway MR, Traul CS, Egan EE. The adult calfactant in acute respiratory distress syndrome trial. Chest 2015;148(2):356–64. PUBMED: 25855884]
69. Wirtz H, Hasenclever D, Schwabe K, Jaschinski U, Weyland A, Kuhnt E, et al. ACE inhibitor for lung protection during mechanical ventilation for acute lung injury-results of the double-blind, placebo controlled, randomised ACEmeVent pilot study. American Journal of Respiratory and Critical Care Medicine. Conference: American Thoracic Society International Conference, ATS 2017. United states 2017;195: no pagination. Embase: 617707751]
70. Zhao WB, Wan SX, Gu DF, Shi B. Therapeutic effect of glucocorticoid inhalation for pulmonary fibrosis in ARDS patients. Medical Journal of Chinese People’s Liberation Army 2014;39(9):741–5. EMBASE: 2014842327]
71. Zheng G, Huang L, Tong H, Shu Q, Hu Y, Ge M, et al. Treatment of acute respiratory distress syndrome with allogeneic adipose-derived mesenchymal stem cells: a randomized, placebo-controlled pilot study. American Journal of Respiratory and Critical Care Medicine. Conference: American Thoracic Society International Conference, ATS 2014;189:no pagination.
72. ∗ Zheng G, Huang L, Tong H, Shu Q, Hu Y, Ge M, et al. Treatment of acute respiratory distress syndrome with allogeneic adipose-derived mesenchymal stem cells: a randomized, placebo-controlled pilot study. Respiratory Research 2014;15(1):39. PUBMED: 24708472]
73. Abraham E, Park YC, Covington P, Conrad SA, Schwartz M. Liposomal prostaglandin E1 in acute respiratory distress syndrome: a placebo-controlled, randomized, double-blind, multicenter clinical trial. Critical Care Medicine 1996;24 (1):10–5. PUBMED: 8565513]
74. Abraham E, Baughman R, Fletcher E, Heard S, Lamberti J, Levy H, et al. Liposomal prostaglandin E1 (TLC C-53) in acute respiratory distress syndrome: a controlled, randomized, double-blind, multicenter clinical trial. TLC C-53 ARDS Study Group. Critical Care Medicine 1999;27 (8):1478–85. PUBMED: 10470753]
75. Annane D, Sebille V, Bellissant E. Effect of low doses of corticosteroids in septic shock patients with or without early acute respiratory distress syndrome. Critical Care Medicine 2006;34(1):22–30. PUBMED: 16374152]
76. Anzueto A, Baughman RP, Guntupalli KK, Weg JG, Wiedemann HP, Raventos AA, et al. Aerosolized surfactant in adults with sepsis-induced acute respiratory distress syndrome. Exosurf Acute Respiratory Distress Syndrome Sepsis Study Group. New England Journal of Medicine 1996; 334(22):1417–21. PUBMED: 8618579]
77. Ardizzoia A, Lissoni P, Tancini G, Paolorossi F, Crispino S, Villa S, et al. Respiratory distress syndrome in patients with advanced cancer treated with pentoxifylline: a randomized study. Support Care in Cancer 1993;1(6): 331–3. PUBMED: 8156252]
78. Bastin AJ, Lagan AL, Mumby S, Quinlan GJ, Griffiths MJD. Effect of N-acetylcysteine in preventing inflammation after lung resection and one-lung ventilation. A randomised controlled trial. American Journal of Respiratory and Critical Care Medicine 2010;181(1):no pagination.
79. Bastin AJ, Davies N, Lim E, Quinlan GJ, Griffiths MJ. Systemic inflammation and oxidative stress post-lung resection: Effect of pretreatment with N-acetylcysteine. Respirology 2016;21(1):180–7. PUBMED: 26503312]
80. Bernard GR, Luce JM, Sprung CL, Rinaldo JE, Tate RM, Sibbald WJ, et al. High-dose corticosteroids in patients with the adult respiratory distress syndrome. New England Journal of Medicine 1987;317(25):1565–70. PUBMED: 3317054]
81. Bernard GR, Wheeler AP, Arons MM, Morris PE, Paz HL, Russell JA, et al. A trial of antioxidants N-acetylcysteine and procysteine in ARDS. The Antioxidant in ARDS Study Group. Chest 1997;112(1):164–72. PUBMED: 9228372]
82. Bernard GR, Wheeler AP, Naum CC, Morris PE, Nelson L, Schein R, et al. A placebo-controlled, randomized trial of IL-10 in acute lung injury (ALI). Chest. 1999; Vol. 116, issue 4 Suppl 2:206S.
83. ∗ Bone RC, Slotman G, Maunder R, Silverman H, Hyers TM, Kerstein MD, et al. Randomized double-blind, multicenter study of prostaglandin E1 in patients with the adult respiratory distress syndrome. Prostaglandin E1 Study Group. Chest 1989;96(1):114–9. PUBMED: 2661155]
84. Slotman GJ, Kerstein MD, Bone RC, Silverman H, Maunder R, Hyers TM, et al. The effects of prostaglandin E1 on non-pulmonary organ function during clinical acute respiratory failure. The Prostaglandin E1 Study Group. Journal of Trauma 1992;32(4):480–8. PUBMED: 1569622]
85. Confalonieri M, Urbino R, Potena A, Piattella M, Parigi P, Puccio G, et al. Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study. American Journal of Respiratory and Critical Care Medicine 2005;171(3):242–8. PUBMED: 15557131]
86. ∗ Cornet AD, Groeneveld AB, Hofstra JJ, Vlaar AP, Tuinman PR, Van Lingen A, et al. Recombinant human activated protein C in the treatment of acute respiratory distress syndrome: a randomized clinical trial. PLOS One 2014;9(3):e90983. PUBMED: 24632673]
87. Cornet AD, Hofstra JJ, Vlaar AP, Tuinman PR, Levi M, Girbes AR, et al. Activated protein C attenuates pulmonary coagulopathy in patients with acute respiratory distress syndrome. Journal of Thrombosis and Haemostasis 2013;11 (5):894–901. PUBMED: 23433188]
88. Domenighetti G, Suter PM, Schaller MD, Ritz R, Perret C. Treatment with N-acetylcysteine during acute respiratory distress syndrome: a randomized, double-blind, placebo-controlled clinical study. Journal of Critical Care 1997;12 (4):177–82. PUBMED: 9459113]
89. Forel JM, Roch A, Marin V, Michelet P, Demory D, Blache JL, et al. Neuromuscular blocking agents decrease inflammatory response in patients presenting with acute respiratory distress syndrome. Critical Care Medicine 2006; 34(11):2749–57. PUBMED: 16932229]
90. Gainnier M, Roch A, Forel JM, Thirion X, Arnal JM, Donati S, et al. Effect of neuromuscular blocking agents on gas exchange in patients presenting with acute respiratory distress syndrome. Critical Care Medicine 2004;32(1): 113–9. PUBMED: 14707568]
91. Gottlieb JE, Elmer M, Steiner R. Efficacy of intravenous ICI 200,880, a neutrophil elastase inhibitor, in the treatment of adult respiratory distress syndrome (ARDS). Chest 1994; 106(Suppl 2):67S.
92. Gregory TJ, Steinberg KP, Spragg R, Gadek JE, Hyers TM, Longmore WJ, et al. Bovine surfactant therapy for patients with acute respiratory distress syndrome. American Journal of Respiratory and Critical Care Medicine 1997;155(4): 1309–15. PUBMED: 9105072]
93. ∗ Holcroft JW, Vassar MJ, Weber CJ. Prostaglandin E1 and survival in patients with the adult respiratory distress syndrome. A prospective trial. Annals of Surgery 1986;203 (4):371–8. PUBMED: 3516085]
94. Holcroft JW, Vassar MJ, Weber CJ. Prostaglandin E1 and survival in patients with the adult respiratory distress syndrome. A prospective trial. Seminars in Respiratory Medicine 1986;7(5):40–7.
95. Hua F, Wang X, Zhu L. Terlipressin decreases vascular endothelial growth factor expression and improves oxygenation in patients with acute respiratory distress syndrome and shock. Journal of Emergency Medicine 2013; 44(2):434–9. PUBMED: 22921855]
96. Jepsen S, Herlevsen P, Knudsen P, Bud MI, Klausen NO. Antioxidant treatment with N-acetylcysteine during adult respiratory distress syndrome: a prospective, randomized, placebo-controlled study. Critical Care Medicine 1992;20 (7):918–23. PUBMED: 1617983]
97. Liu KD, Levitt J, Zhuo H, Kallet RH, Brady S, Steingrub J, et al. Randomized clinical trial of activated protein C for the treatment of acute lung injury. American Journal of Respiratory and Critical Care Medicine 2008;178(6):618–23. PUBMED: 18565951]
98. Markart P, Ruppert C, Wygrecka M, Colaris T, Dahal B, Walmrath D, et al. Patients with ARDS show improvement but not normalisation of alveolar surface activity with surfactant treatment: putative role of neutral lipids. Thorax 2007;62(7):588–94. PUBMED: 17287298]
99. Meduri GU, Headley AS, Golden E, Carson SJ, Umberger RA, Kelso T, et al. Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome: a randomized controlled trial. JAMA 1998;280(2):159–65. PUBMED: 9669790]
100. ∗ Papazian L, Forel JM, Gacouin A, Penot-Ragon C, Perrin G, Loundou A, et al. Neuromuscular blockers in early acute respiratory distress syndrome. New England Journal of Medicine 2010;363(12):1107–16. PUBMED: 20843245]
101. Papazian L, Forel JM, Gacouin A, Perrin G, Jaber S, Arnal JM, et al. Systematic two-day muscle relaxants course in the early phase of severe acute respiratory distress syndrome. A multicenter randomized controlled trial. Intensive Care Medicine 2009;35:S6. Embase: 70190221]
102. Papazian L, Forel JM, Morange S, Barrau K, Penot-Ragon C. Interest of a 48 h systematic paralysis at the early phase, in patients presenting with ARDS. The ACURASYS study. Protocol presentation [Interet d’une curarisation systematique precoce de 48 heures sur le pronostic des patients presentant un syndrome de detresse respiratoire aigue. Etude ACURASYS. Presentation du protocole]. Reanimation 2007;16(1):88–95.
103. Presneill JJ, Harris T, Stewart AG, Cade JF, Wilson JW. A randomized phase II trial of granulocyte-macrophage colony-stimulating factor therapy in severe sepsis with respiratory dysfunction. American Journal of Respiratory and Critical Care Medicine 2002;166(2):138–43. PUBMED: 12119223]
104. Reines HD, Halushka PV, Olanoff LS, Hunt PS. Dazoxiben in human sepsis and adult respiratory distress syndrome. Clinical Pharmacology and Therapeutics 1985;37(4):391–5. PUBMED: 3979000]
105. ∗ Reines HD, Sliverman H, Hurst J, Warren J, Williams J, Rotello L, et al. Effects of two concentrations of nebulized surfactant (Exosurf) in sepsis-induced adult respiratory distress syndrome (ARDS). Critical Care Medicine 1992;20 (4 Suppl):S61.
106. Wiedermann H, Baughman R, DeBoisblanc B, Schuster D, Caldwell E, Weg J, et al. A multicenter trial in human sepsis-induced ARDS of an aerosolized synthetic surfactant (Exosurf). American Review of Respiratory Disease 1992;145 (4 part 2):A184.
107. Rossignon MD, Khayat D, Royer C, Rouby JJ, Jacquillat C, Viars P. Functional and metabolic activity of polymorphonuclear leukocytes from patients with adult respiratory distress syndrome: results of a randomized double-blind placebo-controlled study on the activity of prostaglandin E1. Anesthesiology 1990;72(2):276–81. PUBMED: 2405741]
108. Shoemaker WC. Effectiveness of prostaglandin E1 in adult respiratory distress syndrome. Progress in Clinical and Biological Research 1987;236A:361–81. PUBMED: 3615440]
109. ∗ Shoemaker WC, Appel PL. Effects of prostaglandin E1 in adult respiratory distress syndrome. Surgery 1986;99(3): 275–83. PUBMED: 3513357]
110. Shyamsundar M, O’Kane CM, Calfee C, McKeown ST, Taggart C, Matthay MA, et al. KGF enhances pulmonary production of proepithelial repair factors in a human in vivo model of acute lung injur y. Thorax 2010;65:A47. Embase: 70325792]
111. Steinberg SM, Rodriguez JL, Bitzer LG, Rhee JW, Kelley KA, Flint LM. Indomethacin treatment of human adult respiratory distress syndrome. Circulatory Shock 1990;30 (4):375–84. PUBMED: 2350875]
112. Suter PM, Domenighetti G, Schaller MD, Laverriere MC, Ritz R, Perret C. N-acetylcysteine enhances recovery from acute lung injury in man. A randomized, double-blind, placebo-controlled clinical study. Chest 1994;105(1): 190–4. PUBMED: 8272731]
113. Tuxen DV, Wilson JW, Cade JF. Prevention of lower respiratory herpes simplex virus infection with acyclovir in patients with the adult respiratory distress syndrome. American Review of Respiratory Distress 1987;136(2):402–5. PUBMED: 3039882]
114. Vincent JL, Artigas A, Petersen LC, Meyer C. A multicenter, randomized, double-blind, placebo-controlled, dose-escalation trial assessing safety and efficacy of active site inactivated recombinant factor VIIa in subjects with acute lung injury or acute respiratory distress syndrome. Critical Care Medicine 2009;37(6):1874–80. PUBMED: 19384216]
115. Doig C, Weg JG. Aerosolized surfactant in sepsis-induced adult respiratory distress syndrome. JAMA 1995;273(16): 1259–60. PUBMED: 7715036]
116. ∗ Weg JG, Balk RA, Tharratt RS, Jenkinson SG, Shah JB, Zaccardelli D, et al. Safety and potential efficacy of an aerosolized surfactant in human sepsis-induced adult respiratory distress syndrome. JAMA 1994;272(18): 1433–8. PUBMED: 7933425]
117. Weigelt JA, Norcross JF, Borman KR, Snyder WH 3rd. Early steroid therapy for respiratory failure. Archives of Surgery 1985;120(5):536–40. PUBMED: 3885915]
118. Hegazy S, Helmy T, Salah M. Role of nebivolol therapy in patients with severe acute respiratory distress syndrome. Critical Care Medicine 2016;44(12 Supplement 1):314.
119. Efficacy and safety evaluation of ALT-836 in patients with sepsis and acute lung injury/acute respiratory distress syndrome. www.clinicaltrials.gov/ct2/ show/NCT00879606(first received 10 April 2009).
120. Evaluation of the effect and safety of SURFACEN in the treatment of acute respiratory distress syndrome in adults. rpcec.sld.cu/en/trials/ RPCEC00000126-En (first received 11 April 2012).
121. A multi-centre randomised, placebo controlled trial of nebulised heparin in patients with or at risk of developing acute respiratory distress syndrome, to determine if nebulised heparin improves long term physical function. www.anzctr.org.au/ ACTRN12612000418875.aspx(first received 6 April 2012).
122. Effect of nebulized budesonide on respiratory mechanics and oxygenation in patients with acute lung injury/acute respiratory distress syndrome (ALI/ ARDS). www.anzctr.org.au/ACTRN12615000373572.aspx (first received 13 January 2015).
123. Bellingan G, Brealey D, Mancebo J, Mercat A, Patroniti N, Pettila V, et al. Comparison of the efficacy and safety of FP-1201-lyo (intravenously administered recombinant human interferon beta-1a) and placebo in the treatment of patients with moderate or severe acute respiratory distress syndrome: study protocol for a randomized controlled trial. Trials 2017;18(1):no pagination.
124. Clinical study of rhGM-CSF in the treatment of pulmonary extraneous acute respiratory distress syndrome. www.chictr.org.cn/showproj.aspx?proj= 25020 (first received 31 January 2018).
125. Human umbilical cord derived mesenchymal stem cells therapy in acute respiratory distress syndrome: a pilot study. www.chictr.org.cn/showproj.aspx? proj=25576 (first received 27 February 2018).
126. A comparative, randomised controlled trial for evaluating the efficacy of dexamethasone administration in the treatment of patients with the acute respiratory distress syndrome. www.clinicaltrialsregister.eu/ ctr-search/search?query=eudract number:2012-000775-17 (first received 21 November 2012).
127. A phase 3 clinical study to evaluate the efficacy and safety of intravenous MR11A8 in the treatment of patients with moderate or severe acute respiratory distress syndrome. www.clinicaltrials.jp/ user/showCteDetailE.jsp?japicId=JapicCTI-163320 (first received 19 July 2016).
128. Aspirin as a treatment for ARDS (STAR): a phase 2 randomised control trial. clinicaltrials.gov/ct2/ show/NCT02326350 (first received 29 December 2014).
129. GM-CSF inhalation to improve host defense and pulmonary barrier restoration (GI-HOPE). A randomized, double-blind, parallel group, multicenter, phase II study. www.clinicaltrials.gov/ct2/ show/NCT02595060(first received 3 November 2015).
130. A phase 1/2 study to assess the safety and efficacy of MultiStem® therapy in subjects with acute respiratory distress syndrome. clinicaltrials.gov/ct2/show/ NCT02611609 (first received 23 November 2015).
131. A randomized, blind, placebo-controlled, parallel group, multi-center study to evaluate the safety and dose response relationship of ulinastatin for acute respiratory distress syndrome (ARDS). clinicaltrials.gov/ct2/ show/NCT02895191 (first received 9 September 2016).
132. A phase 2, randomized, double-blind, placebo-controlled, preliminary efficacy study of IC14 in acute respiratory distress syndrome. clinicaltrials.gov/ct2/ show/NCT03017547 (first received 11 January 2017).
133. Repair of acute respiratory distress syndrome by stromal cell administration (REALIST): an open label dose escalation phase 1 trial followed by a randomized, double-blind, placebo-controlled phase 2 trial. clinicaltrials.gov/ct2/show/NCT03042143 (first received 3 February 2017).
134. A phase IIa, placebo controlled, multicenter pilot study to evaluate the safety and efficacy of BIO-11006 inhalation solution in patients with acute respiratory distress syndrome. clinicaltrials.gov/ct2/show/ NCT03202394 (first received 28 June 2017).
135. N-acetylcysteine in early acute respiratory distress syndrome (NARDS). clinicaltrials.gov/show/ NCT03346681 (first received 17 November 2017).
136. Procollagen-3 driven corticosteroids for persistent acute respiratory distress syndrome (ProCoCo). clinicaltrials.gov/ct2/show/nct03371498 (first received 13 December 2017).
137. Human umbilical cord derived mesenchymal stem cells therapy in acute respiratory distress syndrome: a pilot study. clinicaltrials.gov/ct2/show/ NCT03608592 (first received 1 August 2018).
138. A comparative, randomised controlled trial for evaluating the efficacy of dexamethasone in the treatment of patients with acute respiratory distress syndrome. clinicaltrials.gov/ct2/show/NCT01731795 (first received 22 November 2012).
139. ∗ Villar J, Belda J, Añón JM, Blanco J, Pérez-Méndez L, Ferrando C, et al. Evaluating the efficacy of dexamethasone in the treatment of patients with persistent acute respiratory distress syndrome: Study protocol for a randomized controlled trial. Trials 2016 2016;17(342):no pagination.
140. Afshari A, Bastholm Bille A, Allingstrup M. Aerosolized prostacyclins for acute respiratory distress syndrome (ARDS). Cochrane Database of Systematic Reviews 2017, Issue 7. DOI: 10.1002/14651858.CD007733.pub3; PUBMED: 28806480
141. The ARDS Defintion Task Force. Acute respiratory distress syndrome; the Berlin definition. JAMA 2012;307(23): 2526–33. [PUBMED: 22797452]
142. The Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. New England Journal of Medicine 2000;342(18):1301–8. [PUBMED: 10793162] hbaugh 1967
143. Ashbaugh DG, Bigelow DB, Petty TL, Levine BE. Acute respiratory distress in adults. Lancet 1967;2(7511):319–23. [PUBMED: 4143721]
144. Bellani G, Laffey JG, Pham T, Fan E, Brochard L, Esteban A, et al. Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries. JAMA 2016;315(8): 788–800. [PUBMED: 26903337]
145. Bernard GR. N-acetylcysteine in experimental and clinical acute lung injury. American Journal of Medicine 1991;91 (3C):54S–9S. [PUBMED: 1928212]
146. Bernard GR, Artigas A, Brigham KL, Carlet J, Falke K, Hudson L, et al. The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. American Journal of Respiratory and Critical Care Medicine 1994;149(3 Pt 1): 818–24. [PUBMED: 7509706]
147. Bloomfield R, Noble DW, Sudlow A. Prone position for acute respiratory failure in adults. Cochrane Database of Systematic Reviews 2015, Issue 11. DOI: 10.1002/14651858.CD008095.pub2; PUBMED: 26561745
148. Brower RG, Lanken PN, MacIntyre N, Matthay MA, Morris A, Ancukiewicz M, et al. Higher versus lower positive end-expiratory pressures in patients with the acute respiratory distress syndrome. New England Journal of Medicine 2004;351(4):327–36. [PUBMED: 15269312]
149. Chacko B, Peter JV, Tharyan P, John G, Jeyaseelan L. Pressure-controlled versus volume-controlled ventilation for acute respiratory failure due to acute lung injury (ALI) or acute respiratory distress syndrome (ARDS). Cochrane Database of Systematic Reviews 2015, Issue 1. DOI: 10.1002/14651858.CD008807.pub2; PUBMED: 25586462
150. Veritas Health Innovation. Covidence. Version accessed 10 December 2018. Melbourne, Australia: Veritas Health Innovation.
151. Deeks JJ, Higgins JP, Altman DG, editor(s) on behalf of the Cochrane Statistical Methods Group. Chapter 9: Analysing data and undertaking metaanalyses. In: Higgins JP, Churchill R, Chandler J, Cumpston MS editor(s), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), The Cochrane Collaboration, 2017. Available from www.training.cochrane.org/ handbook.
152. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Critical Care Medicine 2008;36(1):296–327. [PUBMED: 18158437]
153. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ (Clinical research ed.) 1997;315(7109):629–34. [PUBMED: 9310563]
154. Thomson Reuters. Endnote X5. Philadelphia (PA): Thomson Reuters, 2011.
155. Feng Y. Efficacy of statin therapy in patients with acute respiratory distress syndrome/acute lung injury: a systematic review and meta-analysis. European Review for Medical and Pharmacological Sciences 2018; Vol. 22, issue 10: 3190–8. [PUBMED: 29863265]
156. The Faculty of Intensive Care Medicine and the Intensive Care Society. Guidelines on the management of acute respiratory distress syndrome. www.ics.ac.uk. Version 1 July 2018 (accessed 10 December 2018).
157. Galvin IM, Steel A, Pinto R, Ferguson ND, Davies MW. Partial liquid ventilation for preventing death and morbidity in adults with acute lung injury and acute respiratory distress syndrome. Cochrane Database of Systematic Reviews 2013, Issue 7. DOI: 10.1002/14651858.CD003707.pub3; PUBMED: 23881653
158. Gao XQ, Li YF, Jiang ZL. Impact of statins on ALI/ARDS: a meta-analysis. Pulmonary Pharmacology and Therapeutics 2016; Vol. 39:85–91. [PUBMED: 27373439]
159. Gebistorf F, Karam O, Wetterslev J, Afshari A. Inhaled nitric oxide for acute respiratory distress syndrome (ARDS) in children and adults. Cochrane Database of Systematic Reviews 2016, Issue 6. DOI: 10.1002/14651858.CD002787.pub3; PUBMED: 27347773
160. McMaster University (developed by Evidence Prime). GRADEpro GDT. Version accessed 25 January 2019. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015.
161. Guay J, Ochroch EA, Kopp S. Intraoperative use of low volume ventilation to decrease postoperative mortality, mechanical ventilation, lengths of stay and lung injury in adults without acute lung injury. Cochrane Database of Systematic Reviews 2018, Issue 7. DOI: 10.1002/14651858.CD011151.pub3; PUBMED: 26641378
162. Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, Schunemann HJ. What is “quality of evidence” and why is it important to clinicians?. BMJ (Clinical research ed.) 2008;336(7651):995–8. [PUBMED: 18456631]
163. Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al. GRADE guidelines: 7. Rating the quality of evidence--inconsistency. Journal of Clinical Epidemiology 2011;64(12):1294–302. [PUBMED: 21803546]
164. Guyatt GH, Oxman AD, Kunz R, Brozek J, Alonso-Coello P, Rind D, et al. GRADE guidelines 6. Rating the quality of evidence--imprecision. Journal of Clinical Epidemiology 2011;64(12):1283–93. [PUBMED: 21839614]
165. Herridge MS, Cheung AM, Tansey CM, Matte-Martyn A, Diaz-Granados N, Al Saidi F, et al Canadian Critical Care Trials Group. One-year outcomes in survivors of the acute respiratory distress syndrome. New England Journal of Medicine 2003;348(8):683–93. [PUBMED: 12594312]
166. Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
167. Higgins JP, Altman DG, Sterne JA, editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), The Cochrane Collaboration, 2017. Available from www.training.cochrane.org/handbook.
168. Hodgson C, Goligher EC, Young ME, Keating JL, Holland AE, Romero L, et al. Recruitment manoeuvres for adults with acute respiratory distress syndrome receiving mechanical ventilation. Cochrane Database of Systematic Reviews 2016, Issue 11. DOI: 10.1002/14651858.CD006667.pub3; PUBMED: 27855477
169. Horita N, Hashimoto S, Miyazawa N, Fujita H, Kojima R, Inoue M, et al. Impact of corticosteroids on mortality in patients with acute respiratory distress syndrome: A systematic review and meta-analysis. Internal Medicine 2015; Vol. 54, issue 12:1473–9. [PUBMED: 26267908]
170. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Critical Care Medicine 2003;31(4):1250–6. [PUBMED: 12682500]
171. Luce JM. Acute lung injury and the acute respiratory distress syndrome. Critical Care Medicine 1998;26(2): 369–76. [PUBMED: 9468178]
172. Lundstrøm LH, Duez CH, Nørskov AK, Rosenstock CV, Thomsen JL, Møller AM, et al. Avoidance versus use of neuromuscular blocking agents for improving conditions during tracheal intubation or direct laryngoscopy in adults and adolescents. Cochrane Database of Systematic Reviews 2017, Issue 5. DOI: 10.1002/14651858.CD009237.pub2; PUBMED: 28513831
173. Meng H, Sun Y, Lu J, Fu S, Meng Z, Scott M, et al. Exogenous surfactant may improve oxygenation but not mortality in adult patients with acute lung injury/acute respiratory distress syndrome: a meta-analysis of 9 clinical trials. Journal of Cardiothoracic & Vascular Anesthesia 2012; Vol. 26, issue 5:849–56. [PUBMED: 22265270]
174. Murray JF, Matthay MA, Luce JM, Flick MR. An expanded definition of the adult respiratory distress syndrome. American Review of Respiratory Disease 1988;138(3):720–3. [PUBMED: 3202424]
175. Nagendran M, McAuley DF, Kruger PS, Papazian L, Truwit JD, Laffey JG, et al. Statin therapy for acute respiratory distress syndrome: an individual patient data meta-analysis of randomised clinical trials. Intensive Care Medicine 2017; Vol. 43, issue 5:663–71. [PUBMED: 28004129]
176. Nanchal RS, Truwit JD. Recent advances in understanding and treating acute respiratory distress syndrome. F1000 Research 2018;7:no pagination. [PUBMED: 30210781]
177. Pehora C, Pearson AM, Kaushal A, Crawford MW, Johnston B. Dexamethasone as an adjuvant to peripheral nerve block. Cochrane Database of Systematic Reviews 2017, Issue 11. DOI: 10.1002/14651858.CD011770.pub2; PUBMED: 29121400
178. Petrucci N, De Feo C. Lung protective ventilation strategy for the acute respiratory distress syndrome. Cochrane Database of Systematic Reviews 2013, Issue 2. DOI: 10.1002/14651858.CD003844.pub4; PUBMED: 23450544
179. Polderman JA, Farhang-Razi V, Van Dieren S, Kranke P, DeVries JH, Hollmann MW, et al. Adverse side effects of dexamethasone in surgical patients. Cochrane Database of Systematic Reviews 2018, Issue 8. DOI: 10.1002/14651858.CD011940.pub2; PUBMED: 30152137
180. Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
181. Santa Cruz R, Rojas JI, Nervi R, Heredia R, Ciapponi A. High versus low end-expiratory pressure (PEEP) levels for mechanically ventilated adult patients with acute lung injury and acute respiratory distress syndrome. Cochrane Database of Systematic Reviews 2013, Issue 6. DOI: 10.1002/14651858.CD009098.pub2; PUBMED: 23740697
182. Society of Critical Care Medicine of Chinese Medical Association. Guideline of the diagnosis and treatment of ALI/ARDS. Chinese Journal of Critical Care Medicine 2006; 18(12):706–10. [PUBMED: 17166345]
183. Schoenfeld DA, Bernard GR. Statistical evaluation of ventilator-free days as an efficacy measure in clinical trials of treatments for acute respiratory distress syndrome. Critical Care Medicine 2002;30(8):1772–7. [PUBMED: 12163791]
184. Singh B, Tiwari AK, Singh K, Singh SK, Ahmed A, Erwin PJ, et al. β2 agonist for the treatment of acute lung injury: a systematic review and meta-analysis. Respiratory Care 2014; Vol. 59, issue 2:288–96. [23777655]
185. Sterne JA, Egger M, Moher D, Boutron I, editor(s). Chapter 10: Addressing reporting biases. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS, editor(s), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), The Cochrane Collaboration, 2017. Available from www.training.cochrane.org/ handbook.
186. Sud S, Sud M, Friedrick JO, Wunsch H, Meade MO, Ferguson ND, et al. High-frequency oscillatory ventilation versus conventional ventilation for acute respiratory distress syndrome. Cochrane Database of Systematic Reviews 2016, Issue 4. DOI: 10.1002/14651858.CD004085.pub4; PUBMED: 27043185
187. Ware LB, Matthay MA. The acute respiratory distress syndrome. New England Journal of Medicine 2000;342(18): 1334–49. [PUBMED: 10793167]
188. Wiedemann HP, Wheeler AP, Bernard GR, Thompson BT, Hayden D, deBoisblanc B, et al. Comparison of two fluid-management strategies in acute lung injury. New England Journal of Medicine 2006;354(24):2564–75. [PUBMED: 16714767]
189. Yang ZG, Lei XL, Li XL. Early application of low-dose glucocorticoid improves acute respiratory distress syndrome: A meta-analysis of randomized controlled trials. Experimental and Therapeutic Medicine 2017; Vol. 13, issue 4:1215–24. [PUBMED: 28413460]
190. Zhang LN, Sun JP, Xue XY, Wang JX. Exogenous pulmonary surfactant for acute respiratory distress syndrome in adults: A systematic review and meta-analysis. Experimental and Therapeutic Medicine 2013; Vol. 5, issue 1:237–42. [PUBMED: 23251275]
191. Zhang Y, Ding S, Li C, Wang Y, Chen Z, Wang Z. Effects of N-acetylcysteine treatment in acute respiratory distress syndrome: A meta-analysis. Experimental and Therapeutic Medicine 2017; Vol. 14, issue 4:2863–8. [PUBMED: 28928799]
192. Adhikari NK, Burns KEA, Meade MO. Pharmacologic therapies for adults with acute lung injury and the acute respiratory distress syndrome. Cochrane Database of Systematic Reviews 2002, Issue 4. DOI: 10.1002/14651858.CD004477 hikari 2004
193. Adhikari NKJ, Burns KEA, Meade MO, Ratnapalan M. Pharmacologic therapies for adults with acute lung injury and acute respiratory distress syndrome. Cochrane Database of Systematic Reviews 2004, Issue 4. DOI: 10.1002/14651858.CD004477.pub2; PUBMED: 15495113